Dow’s game theory
Dow Chemical may have yet to lay out its legal strategy for walking away or delaying its more than $15 billion takeover of Rohm and Haas, but its strategy makes sense from a game-theoretic standpoint, according to JP Morgan analyst Jeffrey Zekauskas. If the court orders Dow to close the transaction after...
Princely Sums
Talk about the end of the salad days. The White House is pledging action against “irresponsible” bonuses for executives at bailed-out Wall Street companies and Senator Claire McCaskill has proposed a law to cap their compensation to $400,000 a year. Masters of Wall Street should not make...
IPOs on horizon in February, but scant new filings in January
Bankers desperate for signs of life in the U.S. IPO market are likely to be buoyed that three are on the calendar in a single week in February, including a $562.5 million offering by Bristol-Myers Squibb offshoot Mead Johnson Nutrition. Hardly a deluge, but not bad after only one IPO in the past six...
Terra Industries’ Maryland defense
Even though fertilizer maker Terra Industries rejected a more than $2 billion takeover offer from rival CF Industries earlier this week, CF has said it is still committed to doing a deal. While CF said it prefers a negotiated transaction, it could launch a hostile bid. So, how are Terra’s defenses...
Talk Me Out of Buying This Stock
Am I crazy — or on to something? From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.
These Tech Stocks Will Make Me Rich
I’m betting real money on these five stocks. From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.
SunPower’s Looking Strong
It’s not all fun in the sun, but this solar shop appears to be secure. From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.
The Gold Purchase Heard ‘Round the World
Newmont sounds the all-clear signal for gold miners. From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.
Mark Your Calendars: The Race Is On!
We’re in the final round of the new hepatitis C drug race. From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.
L-3 Goes to 60
MPH. Not $0. From Fool.com: The Motley Fool. Please read the complete article and let us know what you think below.

« Previous Entries